# Autolus Therapeutics

Source: https://onco.cc/companies/autolus/  
OnCo record `autolus` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

UCL spin-out whose fast-off-rate CD19 CAR-T, obe-cel, was approved for adult ALL in 2024 with lower neurotoxicity than earlier products.

## Summary

Autolus Therapeutics, based in London and listed as AUTL, is a UCL spin-out whose fast-off-rate CD19 CAR-T, obecabtagene autoleucel, was approved for adult acute lymphoblastic leukaemia in 2024 with lower neurotoxicity than earlier products. Obe-cel, sold as Aucatzyl, was approved in the United States on 8 November 2024 and in the United Kingdom and European Union in 2025 for relapsed or refractory adult B-cell ALL on the FELIX trial, manufacturing is in Stevenage, and trials are running in lupus and paediatric ALL. OnCo links it to acute lymphoblastic leukaemia and to the obecabtagene autoleucel drug record. Whether an academic spin-out can manufacture and sell a CAR-T at scale without a large partner is the open question. The FDA approval notice is linked.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- HQ: London
- Type: cell-therapy
- Website: https://www.autolus.com
- Ticker: AUTL

## Sources

- FDA approval notice: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- drugs: [Obecabtagene autoleucel](https://onco.cc/drugs/obecabtagene-autoleucel/)
- trials: [FELIX](https://onco.cc/trials/felix/)
- companies: [Syncona](https://onco.cc/companies/syncona/)
- technologies: [Autologous CAR-T manufacturing, batch by batch](https://onco.cc/technologies/car-t-manufacturing-process/)

---
JSON: https://onco.cc/api/v1/entities/autolus.json